The FDA has approved Roxybond (oxycodone hydrochloride, Protega Pharmaceuticals) immediate-release (IR) Schedule II 10 mg for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
The drug is formulated with abuse-deterrent technology (SentryBond), which combines inactive excipients with active pharmaceutical ingredients to make the tablet more difficult to manipulate for misuse and abuse, even if it is subjected to